CTLA4 and metastatic melanoma: Regarding ICIs for metastatic melanoma, PRO data collected as part of clinical trials generally indicate that quality of life tends to be worse among patients treated with anti-CTLA4 than controls, but quality of life tends to be similar or better in those treated with anti-PD-1 compared to controls.